Home / Expertise / Dispute Resolution / Life Sciences Disputes

Life Sciences Disputes

United Kingdom

Our Life Sciences disputes and investigations specialists advise clients across the breadth of the sector, including pharmaceutical, medical device and biotech companies. 

We offer: 

  • Quality and depth of resources. With more than 900 dispute resolution specialists, we have the expertise and capacity to handle the most complex disputes. 
  • Global reach with local insight. We think and act internationally while delivering local results.
  • Proven high-stakes advisers. Clients trust us with their most sensitive, difficult and business-critical cases.
  • Sector specialists. We work with industry experts to provide you with commercial legal solutions to your industry-specific issues.

Highlights of our recent experience:

  • GlaxoSmithKline as the lead appellant in the first ever reference to the European Court of Justice (CJEU) by the Competition Appeal Tribunal (CAT) in the paroxetine case.
  • The Association of British Pharmaceutical Industry (ABPI) in relation to its role as an interested party in appeal to the Court of Appeal of a judicial review brought by Bayer and Novartis against NHS Darlington CCG and Others regarding the use of unlicensed products when a licenced product was available.
  • Teva Europe in relation to an application at the European General Court for annulment of the Commission Decision refusing a marketing authorisation for Teva’s generic cabazitaxel product due to regulatory exclusivity said to exist for the reference product.
  • Sandoz in relation to patent infringement proceedings, a regulatory challenge against its pharmaceutical product marketing authorisation, and its claim on the cross-undertaking in damages against Napp Pharmaceuticals, significantly larger than any that have preceded it.
  • Various clients in relation to group litigation orders or threatened group litigation orders arising out of product liability claims.
  • The ABPI and the Association of British HealthTech Industries to intervene in the Supreme Court appeal in Lloyd v Google, the leading data protection class action.
  • Takeda in relation to a £500m+ shareholder dispute arising out of an acquisition of a global pharmaceutical company.
  • A global healthcare company in relation to the defence of a claim by a distributor for breach of a pharmaceutical exclusive distributorship agreement and for a mandatory injunction requiring the client to continue to supply.
  • A multi-national pharmaceutical company in relation to internal investigations and responding to the regulator on whistleblowers‘ allegations.
  • A drug wholesaler in relation to a dispute regarding an exclusive distribution agreement between a Canadian pharmaceutical wholesale supplier and an Indian drug manufacturer whose product had consistently failed to meet regulatory standards and testing requirements.
  • A UK-based institution in relation to legal and commercial matters relating to its Covid-19 vaccine development programme.
Read more Read less

"CMS is one of the strongest city firms in this sector. They have real and deep rooted expertise in regulatory issues and in litigation involving medical devices."

Life Sciences, Legal 500 UK, 2021

"They deliver a Rolls-Royce service to some of the world’s most successful life sciences companies – many of whom they have deservedly achieved coveted “trusted adviser” status. They are one of the elite departments in this field. It is unsurprising that they have such a loyal client base."

Life Sciences, Legal 500 UK, 2021

"They provide excellent advice."

Life Sciences, Chambers UK, 2021

“A 21st century 24/7 powerhouse."

Commercial Litigation, Legal 500, 2021

Feed

Show only
11 March 2021
Man­aging in­vest­ig­a­tions: plan­ning pres­sures and pit­falls video series
With more in­tern­al re­port­ing of con­cerns with­in busi­nesses thanks to im­proved train­ing and con­trols, and with com­plex reg­u­lat­ory, crim­in­al and HR in­vest­ig­a­tions be­com­ing more com­mon­place, cor­por­ates need...
23 February 2021
CMS Guide to Anti-Bribery and Cor­rup­tion Laws
We are de­lighted to present the sixth edi­tion of the CMS Guide to Anti-Bribery and Cor­rup­tion Laws
23 February 2021
Hard to swal­low: breaches of con­tract do not al­ways lead to re­cov­er­able...
In a case arising out of an anti-com­pet­i­tion clause in a man­u­fac­tur­ing and dis­tri­bu­tion agree­ment for a med­ic­al com­pound, the High Court has held that no loss was suffered des­pite mean­ing­ful pre­par­at­ory...
26 January 2021
CMS Ex­pert Guide to European class ac­tions
Class ac­tions have been on the rise in Europe for a num­ber of years, but the rate is ac­cel­er­at­ing. New pro­ced­ur­al devices in­ten­ded to bet­ter fa­cil­it­ate col­lect­ive re­dress con­tin­ue to be in­tro­duced. Of­ten...
Comparable
December 2019
In­ter­na­tion­al Dis­putes Di­gest - Winter Edi­tion 2019
Back to main page Wel­come to the winter edi­tion of our In­ter­na­tion­al Dis­putes Di­gest, a bi-an­nu­al pub­lic­a­tion fea­tur­ing ana­lys­is and com­ment­ary on the key trends cur­rently shap­ing the glob­al dis­pute res­ol­u­tion...